EGFR and pancreatic neoplasm: The humanized EGFR-targeting antibody LR004 showed anti-tumor activity when given as a single treatment in MIA PaCa-2 and PANC-1 pancreatic tumor models, with the response potentiated when multiple doses were given [35].